148 related articles for article (PubMed ID: 17505923)
1. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda.
Stangl AL; Wamai N; Mermin J; Awor AC; Bunnell RE
AIDS Care; 2007 May; 19(5):626-36. PubMed ID: 17505923
[TBL] [Abstract][Full Text] [Related]
2. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
3. Determinants of health-related quality of life in HIV-infected patients.
Murri R; Fantoni M; Del Borgo C; Visona R; Barracco A; Zambelli A; Testa L; Orchi N; Tozzi V; Bosco O; Wu AW
AIDS Care; 2003 Aug; 15(4):581-90. PubMed ID: 14509872
[TBL] [Abstract][Full Text] [Related]
4. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda.
Bajunirwe F; Tisch DJ; King CH; Arts EJ; Debanne SM; Sethi AK
AIDS Care; 2009 Mar; 21(3):271-9. PubMed ID: 19280404
[TBL] [Abstract][Full Text] [Related]
6. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
[TBL] [Abstract][Full Text] [Related]
8. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
9. Evaluating health-related wellbeing outcomes among outpatient adults with human immunodeficiency virus infection in the HAART era.
Saunders DS; Burgoyne RW
Int J STD AIDS; 2002 Oct; 13(10):683-90. PubMed ID: 12396538
[TBL] [Abstract][Full Text] [Related]
10. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M
HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
[TBL] [Abstract][Full Text] [Related]
11. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
[TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
13. The impact of highly active antiretroviral therapy on activities of daily living in HIV-infected adults in South Africa.
Kakinami L; de Bruyn G; Pronyk P; Mohapi L; Tshabangu N; Moshabela M; McIntyre J; Martinson NA
AIDS Behav; 2011 May; 15(4):823-31. PubMed ID: 20703794
[TBL] [Abstract][Full Text] [Related]
14. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
16. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
17. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.
Powers AE; Marden SF; McConnell R; Leidy NK; Campbell CM; Soeken KL; Barker C; Davey RT; Dybul MR
AIDS; 2006 Apr; 20(6):837-45. PubMed ID: 16549967
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
[TBL] [Abstract][Full Text] [Related]
20. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
